Last updated: April 25, 2026
What firms supply treprostinil diolamine API?
Public supplier visibility for treprostinil diolamine is limited because filings and tenders often list manufacturing sites, not branded “diolamine salt” suppliers. Where treprostinil appears in procurement and regulatory contexts, it is frequently supplied as treprostinil (base) or as a salt formed from treprostinil base using diolamine. As a result, the most reliable supplier set is the overlap between:
1) API producers that supply treprostinil (base), and
2) commercial manufacturers that are known to handle salt formation with standard bases such as diolamine for pharmaceutical salts.
Actionable procurement approach (industry standard): qualify either (a) direct API manufacturers supplying treprostinil diolamine as a finished salt, or (b) treprostinil base suppliers that can perform validated salt formation to diolamine at the same GMP site.
Which suppliers are consistently linked to treprostinil manufacturing?
The following supplier set is the core group that repeatedly appears across treprostinil supply chains in regulatory and commercial manufacturing contexts. (Where the market public record indicates treprostinil API supply, the same API supply base is typically used to generate the diolamine salt under GMP salt-formation operations.)
| Supplier |
Likely commercial role in treprostinil supply |
Evidence anchor type |
Treprostinil salt relevance (diolamine) |
| United Therapeutics Corporation (brand owner) |
Drug product and manufacturing ecosystem |
Regulatory dossier and product ecosystem |
Salt form used in commercial products; direct sourcing controls often flow from internal API and downstream manufacturing partnerships |
| Teva Pharmaceuticals |
API and/or commercial supply via contract manufacturing ecosystem |
Company public regulatory and supply footprint |
Salt formation can be performed at site or via qualified partners; diolamine salt is a known salt form in treprostinil products |
| Sagent Pharmaceuticals / Cipla group supply chain history |
API supply and/or CMO role for inhaled/IV therapy supply chains |
Public procurement and supply-chain activity |
Treprostinil base-to-salt conversions are common in CMO salt formation programs |
| Hikma Pharmaceuticals |
CMO/API ecosystem presence |
Regulatory and market activity footprint |
Salt-formation typically supported for controlled salts |
| Zydus Lifesciences |
API and/or CMO role for respiratory and cardiovascular specialty products |
Regulatory and commercial footprint |
Treprostinil base supply can be converted to diolamine salt if supported by solid-state controls |
| Lupin |
API supply in specialty portfolios |
Regulatory footprint |
Salt-formation capability is standard for specialty injectables and inhalation salts |
| Mylan / Viatris legacy supply ecosystem |
API and/or CMO role |
Company footprint |
Enables base-to-salt conversion under GMP |
| Contract salt-formation and API manufacturing networks (EU/US/India CMOs) |
Salt formation and API manufacturing |
Industry practice |
Diolamine is a standard base used in pharmaceutical salt manufacturing; capability is assessed via process validation and solid-state characterization |
Note: The treprostinil diolamine-specific label “diolamine salt” is often applied late in the manufacturing chain; the API supplier may still be treprostinil base, with salt conversion performed either by the same company or a downstream qualified salt-formation site.
Which suppliers are relevant by therapeutic product linkage (treprostinil product portfolio)?
Treprostinil products are used for pulmonary arterial hypertension (PAH) and are marketed in multiple dosage forms (injectable, inhaled, and formulations that depend on the salt form). The supplier ecosystem for the underlying API is anchored by the brand owner’s qualified network.
Procurement lens: if you are buying treprostinil diolamine, you typically qualify one of two supply models:
Model 1: Direct salt supplier
- Supplier sells treprostinil diolamine (salt) as a discrete SKU under GMP.
- Requires salt-specific CoA, salt-specific specs, and solid-state characterization (e.g., PXRD/DSC) in the QC package.
Model 2: Base supplier plus salt formation at GMP site
- Supplier sells treprostinil base and then performs diolamine salt formation at the same site or a controlled partner site.
- Requires validated conversion process, controlled residual solvent/water limits, and reproducible polymorph/solvate control.
What to request in a supplier qualification package for treprostinil diolamine
Even when the supplier list is visible, the deliverable that matters for treprostinil diolamine is the salt identity, solid state, and impurities. For procurement and R&D planning, request the following from any candidate supplier:
| Qualification element |
Supplier deliverable to demand |
| Salt identity |
Certificate of Analysis referencing treprostinil diolamine; analytical method summary for identity (typ. spectroscopy/thermal/XRD) |
| Solid-state form |
PXRD and/or DSC characterization report tied to the commercial lot history |
| Impurity profile |
Spec limits for residual diolamine and general treprostinil-related impurities; enantiomeric and degradation impurity coverage where applicable |
| Residuals |
Residual solvent statement (as applicable) and water content limits |
| Process reproducibility |
Batch production record summary and change control history for the salt formation step |
| Stability |
Real-time and accelerated stability indicating no conversion to other forms |
This is where supplier capability differences show up even when multiple firms can provide “treprostinil.”
How procurement should be structured for speed and risk control
For treprostinil diolamine, procurement risk concentrates in the salt-formation step. A supplier strategy that reduces timeline variance:
1) Two qualified sources for treprostinil base
2) One qualified salt-formation pathway that either is (a) in-house or (b) uses a contracted salt-formation site under the supplier’s GMP umbrella
3) Single spec package alignment: ensure both sources deliver identical salt-specific CoA testing and solid-state controls
Which intermediates matter for building/validating treprostinil diolamine supply?
Treprostinil diolamine is formed from treprostinil base plus diolamine. In supplier qualification, the intermediates that typically require documentation are the upstream API intermediates that drive impurity levels rather than the salt itself. For procurement, focus on:
- Treprostinil base intermediate lineage (controls for key impurities)
- The final API step before salt formation (to avoid degradation during salt conversion)
- Salt-formation solvents and drying conditions (to control residual solvent and water)
- Diolamine source purity and grade (food/pharma grade diolamine differs by supplier)
Key takeaways
- Treprostinil diolamine supply typically depends on treprostinil base supply plus GMP salt formation using diolamine.
- Publicly visible “diolamine salt” supplier labels are often incomplete; the actionable supplier map is the overlap of treprostinil API manufacturers and qualified salt-formation operations.
- Qualification should be anchored on salt identity, solid-state form, residual diolamine controls, and full impurity specs.
FAQs
1) Is treprostinil diolamine usually supplied as an isolated API salt SKU?
Often it is supplied as treprostinil base with salt formation performed under the supplier’s GMP control, or the supplier sells the salt SKU with a salt-formation step documented in the batch record.
2) What is the most common procurement risk for treprostinil diolamine?
Salt-formation reproducibility: solid-state form changes and residuals (diolamine and solvents/water) that alter specs and stability.
3) Can treprostinil base suppliers qualify for treprostinil diolamine without direct “diolamine salt” history?
Yes if they can execute validated diolamine salt formation with documented identity, solid-state characterization, and stability.
4) What documentation differentiates a capable supplier from a nominal one?
Salt-specific identity methods, PXRD/DSC lot history, residual diolamine limits, impurity specs tied to the salt process, and stability data for the salt form.
5) How many suppliers are optimal for commercial continuity?
Two for treprostinil base plus one validated salt-formation pathway aligned to your spec package.
References
[1] United Therapeutics Corporation. Regulatory and product documentation for treprostinil-based therapies (company filings and public product information).
[2] EMA and FDA product/regulatory listings for treprostinil formulations and associated API salt forms.
[3] General GMP salt-formation expectations in pharmaceutical quality systems (identity, solid-state characterization, stability, and impurity controls) as reflected in regulatory CMC review practices.
